Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis

Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has initiated a Phase 1/2a clinical trial for ARO-MMP7, targeting matrix metalloproteinase 7 (MMP7) to treat idiopathic pulmonary fibrosis (IPF). The trial, AROMMP7-1001, will assess safety, tolerability, pharmacokinetics, and pharmacodynamics in up to 56 healthy volunteers and 21 IPF patients. MMP7 is implicated in IPF's progression, causing inflammation and fibrosis. The trial’s results could address the significant unmet medical need for IPF patients, aiming to enhance lung function beyond current therapies. The ongoing research may position Arrowhead favorably in the competitive biotech landscape.

Positive

• Initiation of Phase 1/2a clinical trial for ARO-MMP7.
• Potential to address significant unmet medical need in IPF treatment.
• Involvement of up to 56 healthy volunteers and 21 IPF patients in the study.

Negative

• None.

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce the expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF).

“MMP7 is thought to play multiple roles in IPF pathogenesis, including promoting inflammation and aberrant epithelial repair and fibrosis,” said James Hamilton, M.D., MBA, chief of discovery and translational medicine at Arrowhead. “ARO-MMP7 offers a novel approach to potentially address the significant unmet medical need that exists for patients with IPF, who experience progressive decline of lung function, despite currently available therapies.”

AROMMP7-1001 (NCT05537025) is a Phase 1/2a single ascending dose and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-MMP7 in up to 56 healthy volunteers and up to 21 patients with IPF.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” or “continue” are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230202005288/en/

Arrowhead Pharmaceuticals, Inc.

Vince Anzalone, CFA

626-304-3400

ir@arrowheadpharma.com



Investors:

LifeSci Advisors, LLC

Brian Ritchie

212-915-2578

britchie@lifesciadvisors.com

www.lifesciadvisors.com



Media:

LifeSci Communications, LLC

Josephine Belluardo, Ph.D.

646-751-4361

jo@lifescicomms.com

www.lifescicommunications.com

Source: Arrowhead Pharmaceuticals Inc.

FAQ

What is the purpose of the ARO-MMP7 clinical trial by Arrowhead Pharmaceuticals?

The ARO-MMP7 clinical trial aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-MMP7 as a potential treatment for idiopathic pulmonary fibrosis (IPF).

What does MMP7 do in the context of idiopathic pulmonary fibrosis (IPF)?

MMP7 is believed to promote inflammation and aberrant epithelial repair, contributing to the progression of IPF.

What is the expected outcome of the ARO-MMP7 trial for ARWR shareholders?

Positive results from the ARO-MMP7 trial could increase investor confidence and influence the stock price favorably, indicating progress in addressing an unmet medical need.

How many subjects are involved in the ARO-MMP7 clinical trial?

The ARO-MMP7 clinical trial will involve up to 56 healthy volunteers and 21 patients with idiopathic pulmonary fibrosis (IPF).

Where can I find more information about the ARO-MMP7 trial?

More information about the ARO-MMP7 trial can be found on the clinical trials registry under the identifier NCT05537025.